Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios A Dimopoulos

Showing results (361-370 of 740) with videos related to

Pageof 74
Sort By:
Advances in Therapy|June 28, 2022
Correction to: Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysisThierry Facon, Jesús San-Miguel, Meletios A Dimopoulos, et al.
European Journal of Cancer (Oxford, England : 1990)|November 25, 2018
All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myelomaMeletios A Dimopoulos, Sebastian Grosicki, Wiesław W Jędrzejczak, et al.
International Journal of Hematology|August 8, 2019
Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. TrialsMeletios A Dimopoulos, Philippe Moreau, Shinsuke Iida, et al.
Haematologica|February 8, 2006
Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myelomaMeletios A Dimopoulos, Athanasios Anagnostopoulos, Evangelos Terpos, et al.
Clinical Breast Cancer|April 8, 2014
Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancerGeorge Pentheroudakis, Vassiliki Kotoula, George Kouvatseas, et al.
American Journal of Hematology|January 13, 2022
Third dose of the BNT162b2 vaccine results in very high levels of neutralizing antibodies against SARS-CoV-2: Results of a prospective study in 150 health professionals in GreeceEvangelos Terpos, Vangelis Karalis, Aimilia D Sklirou, et al.
Haematologica|May 13, 2010
Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myelomaJean-Luc Harousseau, Meletios A Dimopoulos, Michael Wang, et al.
American Journal of Hematology|May 24, 2021
Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?Evangelos Terpos, Ioannis P Trougakos, Vangelis Karalis, et al.
American Journal of Hematology|May 30, 2012
Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patientsLia A Moulopoulos, Meletios A Dimopoulos, Efstathios Kastritis, et al.
Haematologica|November 21, 2007
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasoneEfstathios Kastritis, Athanasios Anagnostopoulos, Maria Roussou, et al.
Pageof 74

Showing results (361-370 of 740) with videos related to

Sort By:
Pageof 74
Advances in Therapy|June 28, 2022
Correction to: Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysisThierry Facon, Jesús San-Miguel, Meletios A Dimopoulos, et al.
European Journal of Cancer (Oxford, England : 1990)|November 25, 2018
All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myelomaMeletios A Dimopoulos, Sebastian Grosicki, Wiesław W Jędrzejczak, et al.
International Journal of Hematology|August 8, 2019
Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. TrialsMeletios A Dimopoulos, Philippe Moreau, Shinsuke Iida, et al.
Haematologica|February 8, 2006
Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myelomaMeletios A Dimopoulos, Athanasios Anagnostopoulos, Evangelos Terpos, et al.
Clinical Breast Cancer|April 8, 2014
Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancerGeorge Pentheroudakis, Vassiliki Kotoula, George Kouvatseas, et al.
American Journal of Hematology|January 13, 2022
Third dose of the BNT162b2 vaccine results in very high levels of neutralizing antibodies against SARS-CoV-2: Results of a prospective study in 150 health professionals in GreeceEvangelos Terpos, Vangelis Karalis, Aimilia D Sklirou, et al.
Haematologica|May 13, 2010
Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myelomaJean-Luc Harousseau, Meletios A Dimopoulos, Michael Wang, et al.
American Journal of Hematology|May 24, 2021
Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?Evangelos Terpos, Ioannis P Trougakos, Vangelis Karalis, et al.
American Journal of Hematology|May 30, 2012
Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patientsLia A Moulopoulos, Meletios A Dimopoulos, Efstathios Kastritis, et al.
Haematologica|November 21, 2007
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasoneEfstathios Kastritis, Athanasios Anagnostopoulos, Maria Roussou, et al.
Pageof 74